Psychiatric Services
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Citrome, L.
* Articles by Tracy, K. A.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Citrome, L.
* Articles by Tracy, K. A.
Related Collections
* Violence in Treatment Settings
* Schizophrenia Spectrum Disorders
* Atypical Neuroleptics
Psychiatr Serv 55:290-294, March 2004
© 2004 American Psychiatric Association

Adjunctive Divalproex and Hostility Among Patients With Schizophrenia Receiving Olanzapine or Risperidone

Leslie Citrome, M.D., M.P.H., Daniel E. Casey, M.D., David G. Daniel, M.D., Patricia Wozniak, Ph.D., Lisa D. Kochan, R.Ph., Ph.D. and Katherine A. Tracy, M.D., Ph.D.

OBJECTIVE: This study compared the specific antihostility effects of atypical antipsychotic monotherapy (olanzapine or risperidone) with that of combination treatment with divalproex sodium among patients with schizophrenia experiencing an acute psychotic episode. METHODS: A total of 249 inpatients with schizophrenia were randomly assigned to receive olanzapine plus placebo, olanzapine plus divalproex, risperidone plus placebo, or risperidone plus divalproex in a double-blind, 28-day multicenter trial. The target daily dose was 15 milligrams for olanzapine, 6 milligrams for risperidone, and up to 30 milligrams per kilogram (minimum, 15 milligrams per kilogram) for divalproex. The hostility item of the Positive and Negative Syndrome Scale (PANSS) was the principal outcome measure. Covariates included the PANSS items reflecting positive symptoms of schizophrenia (delusions, suspiciousness/persecution, grandiosity, unusual thought content, conceptual disorganization, and hallucinatory behavior). RESULTS: Combination treatment with risperidone or olanzapine plus divalproex was associated with different scores on the hostility item of the PANSS compared with antipsychotic monotherapy. Combination therapy had a significantly greater antihostility effect at days 3 and 7 than monotherapy. This result was not seen beyond the first week of treatment, but there was a trend toward a difference in effect for the entire treatment period. The effect on hostility appears to be statistically independent of antipsychotic effect on other PANSS items reflecting delusional thinking, a formal thought disorder, or hallucinations. CONCLUSIONS: Divalproex sodium may be useful as an adjunctive agent in specifically reducing hostility in the first week of treatment with risperidone or olanzapine among patients with schizophrenia experiencing an acute psychotic episode.




This article has been cited by other articles:


Home page
J. Neuropsychiatry Clin. Neurosi.Home page
M. J. Hoptman, J. Volavka, P. Czobor, G. Gerig, M. Chakos, J. Blocher, L. L. Citrome, B. Sheitman, J.-P. Lindenmayer, J. A. Lieberman, et al.
Aggression and Quantitative MRI Measures of Caudate in Patients With Chronic Schizophrenia or Schizoaffective Disorder
J Neuropsychiatry Clin Neurosci, November 1, 2006; 18(4): 509 - 515.
[Abstract] [Full Text] [PDF]


Home page
Psychiatr. Serv.Home page
R. Eilers
Antihostility Effects of Adjunctive Divalproex
Psychiatr Serv, September 1, 2004; 55(9): 1068 - 1068.
[Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2004 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org